← Back

Amphastar P

Amphastar Pharmaceuticals, Inc., a bio-pharmaceutical company, develops, manufactures, markets, and sells generic and proprietary injectable, inhalation, and intranasal products in the United States, China, and France. It offers BAQSIMI, a dry nasal spray used in an emergency for the treatment of severe hypoglycemia; Primatene MIST, an epinephrine inhalation product for the temporary relief of mild symptoms of intermittent asthma; Glucagon for injection emergency kit; Enoxaparin, an injectable form of low molecular weight heparin for the prevention and treatment of deep vein thrombosis; and REXTOVY and Naloxone for opioid overdose. The company also provides Cortrosyn, a lyophilized power for use as a diagnostic agent in the screening of patients with adrenocortical insufficiency; Amphadase, a bovine-sourced hyaluronidase injection; Epinephrine injection for allergic reactions; Lidocaine jelly, an anesthetic product for urological procedures; Lidocaine topical solution for various procedures; Phytonadione injection, a vitamin K1 injection for newborn babies; and emergency syringe products, including atropine, calcium chloride, dextrose, epinephrine, lidocaine, and sodium bicarbonate. In addition, it offers Albuterol sulfate inhalation aerosol for the treatment or prevention of bronchospasm; Iron sucrose injection, an iron replacement product for the treatment of iron deficiency anemia in patients with chronic kidney disease; Teriparatide injection for managing daily osteoporosis therapy; and Ipratropium Bromide HFA inhalation aerosol, an anticholinergic indicated for the maintenance treatment of bronchospasm associated with chronic obstructive pulmonary disease. Further, the company provides active pharmaceutical ingredient (API) products, such as Recombinant Human Insulin and porcine insulin API. The company was founded in 1996 and is headquartered in Rancho Cucamonga, California.

Price · split & dividend adjusted
News & notes moving AMPH
AMPH▲

ANI Pharmaceuticals Leads Q2 Revenue Growth But Guides Weakest

ANI Pharmaceuticals reported second-quarter revenues of $266 million, up 25.9% year on year, beating analysts' expectations by 2.4%, but its full-year revenue guidance slightly missed estimates, making it the weakest guidance update among the four generic pharmaceuticals stocks tracked. The group as a whole beat consensus revenue estimates by 2.6%, with Amphastar Pharmaceuticals posting revenues of $183.9 million, up 5.4% year on year and beating expectations by 2%, while Viatris reported revenues of $3.76 billion, up 4.9% year on year and exceeding expectations by 2.2%, and Amneal reported revenues of $796.2 million, up 9.9% year on year and beating expectations by 3.6%. Despite the strong revenue performance, share prices of the four companies have fallen an average of 5.6% since their latest earnings results, with ANI Pharmaceuticals down 9.1% to $75.12, Viatris down 7.6% to $16.32, Amneal down 8.3% to $17.52, and Amphastar up 2.3% to $20.28.
ANIP ▼AMPH ▲AMRX ▼VTRS ▼
Yahoo Finance·11dRead more ▾
AMPH▼

Amphastar expects $2M-$3M quarterly IMS remediation costs, maintains 2026 sales growth outlook

Amphastar Pharmaceuticals anticipates $2 million to $3 million per quarter in additional expenses for several quarters due to remediation efforts at its IMS subsidiary, which recently received an FDA warning letter, while maintaining its overall corporate sales growth guidance of mid-single digit to high single-digit for 2026. The warning letter does not require IMS to stop manufacturing or distributing products, and management does not expect a material adverse effect on overall business operations. BAQSIMI generated $178.3 million in net sales, exceeding the $175 million threshold and triggering a first milestone payment to Lilly, with a milestone-triggering contract year and a $100 million payment due in Q3 2026. Second-quarter revenue rose 5% to $183.9 million, driven by the launch of Ipratropium Bromide Inhalation with $8.4 million in sales, while BAQSIMI net sales decreased 3% to $45.5 million due to pricing and rebate dynamics. The company also accelerated share repurchases, buying back approximately $45 million in the quarter, and reported adjusted net income of $40.8 million, or $0.91 per share.
AMPH ▼LLY ▲
Seeking Alpha·20dRead more ▾
© 2026 MarketDXAsset